Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial

AIMS: The efficacy and safety of insulin degludec (IDeg) was compared with insulin detemir (IDet), both administered once daily (OD) as basal treatment in participants with type 1 diabetes mellitus (T1DM). The primary outcome was non-inferiority of IDeg to IDet in glycated haemoglobin (HbA1c) reduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, M J, Gross, J L, Ono, Y, Sasaki, T, Bantwal, G, Gall, M A, Niemeyer, M, Seino, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237553/
https://www.ncbi.nlm.nih.gov/pubmed/24702700
http://dx.doi.org/10.1111/dom.12298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237553/
https://www.ncbi.nlm.nih.gov/pubmed/24702700
http://dx.doi.org/10.1111/dom.12298

Ejemplares similares